NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin

The pathophysiology of body weight gain that is observed in patients suffering from myeloproliferative neoplasms treated with inhibitors of the janus kinase (Jak) 1 and 2 pathway remains unknown. Here we hypothesized that this class of drugs interferes with the metabolic actions of leptin, as this h...

Full description

Bibliographic Details
Main Authors: Magalie Haissaguerre, Amandine Ferriere, Samantha Clark, Omar Guzman-Quevedo, Antoine Tabarin, Daniela Cota
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2018.00527/full